Compare AbCellera Biologics Inc (ABCL) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? AbCellera Biologics Inc trades at $9.21 (market cap $2.85B), while First Trust NASDAQ 100 Technology Index Fund trades at $315.63. Which is the better fit depends on your goals.
| ABCL | QTEC | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $9.76 | $335.74 |
52-Week Low | $2.78 | $207.03 |
Enterprise Value | $2.45B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
QTEC trades at $316.59, up 1.7% with a bullish technical signal from moving averages. The ETF, tracking NASDAQ-100 technology stocks, lacks disclosed P/E and P/S ratios. A small dividend of $0.03 is scheduled for June 2026, with support at $313 and resistance at $319.
Outlook remains positive due to strong technical momentum, though overbought RSI signals caution. Risks include tech sector volatility and reliance on broad market trends. Analyst coverage highlights its role for diversified tech exposure without specific ratings available.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
